November 19, 2025, 10:30 AM – 12:00 PM EST
Immuno-Oncology (IO) is experiencing a pivotal moment. After a decade of extraordinary promise and rapid investment, the field has faced a series of clinical setbacks that have cooled investor enthusiasm and shifted attention toward other oncology innovations such as antibody-drug conjugates (ADCs) and radioligand therapies (RLTs). Yet, the core biological rationale for IO remains compelling — and a new wave of next-generation biologic modalities, from bispecific constructs to in vivo CAR-T therapies, is poised to reshape the therapeutic landscape.
Timed just after the 40th Anniversary SITC Annual Meeting, this 90-minute live webinar will bring together leading scientists, biotech innovators, and investment strategists for a candid, forward-looking discussion. Together, we will explore how IO can navigate the current funding climate, leverage cutting-edge science, and re-engage stakeholders with a compelling vision for the future.
Key Takeaways and Insights:
- Survival & Growth in Tight Markets — Learn creative ways for early-stage IO companies to sustain R&D progress, generate impactful data, and communicate value despite funding constraints.
- Breakthrough Modalities & Mechanisms — Explore the next-gen biologics and novel mechanisms of action likely to define IO in 2026 and beyond, with lessons learned from SITC 2025.
- Strategic Development Approaches — Identify smarter clinical trial designs and combination strategies that maximize translational impact and investor confidence.
Speakers:
- Mike Curran, PhD, Professor of Immunology and Co-Founder of Oncology Research for Biologics and Immunotherapy Translation (ORBIT) at MD Anderson Cancer Center, Founder and Scientific Advisory Board Head, ImmunoGenesis
- Llew Keltner, MD, PhD, CEO, Epistat
- Paul Rennert, PhD, CSO & President, Aleta Bio
- Asthika Goonewardene, MBA, Managing Director, Truist
- Søren Bregenholt, CEO, Alligator Bioscience
